Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide. 1985

G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti

69 patients with unresectable non-small cell lung cancer, previously untreated, received cisplatin 100 mg/m2 on day 1 and etoposide 120 mg/m2 on days 4, 6, 8 at 4-week intervals. 66 patients were evaluable for tumor response and toxicity. Overall objective response was 25.7% (3 complete responses and 14 partial responses). Response rate in limited disease was 41% and in patients with performance score 0 it was 40%. Squamous cell carcinoma and adenocarcinoma responded in 31 and 24% of evaluable patients. Complete response was associated with a long duration of remission. Median survival time of responding patients was significantly superior to the median of nonresponding patients (p less than 0.001) but compared to stable disease no statistical significance was demonstrable (p greater than 0.05). Hematological and renal toxicity of proposed regimen was generally mild. Nausea and vomiting were the most noxious side effects.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
May 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
April 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
November 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
April 1998, European journal of cancer (Oxford, England : 1990),
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
April 1985, Cancer treatment reports,
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
October 1988, American journal of clinical oncology,
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
May 1986, Cancer treatment reports,
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
May 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
September 1986, Seminars in oncology,
G V Scagliotti, and D Lodico, and F Gozzelino, and F Bardessono, and C Albera, and E Gatti, and G Pescetti
November 2004, Ai zheng = Aizheng = Chinese journal of cancer,
Copied contents to your clipboard!